Yet Y Yan1, John P Walsh2, Peter L Munk2, Paul I Mallinson2, Christine Simmons3, Paul W Clarkson4, Prem R Jayaram2, Manraj K S Heran5, Hugue A Ouellette2. 1. Musculoskeletal Section, Department of Radiology, Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Radiology, Changi General Hospital, Singapore. Electronic address: yanyetyen@gmail.com. 2. Musculoskeletal Section, Department of Radiology, Vancouver General Hospital, Vancouver, British Columbia, Canada. 3. Medical Oncology Service, British Columbia Cancer Agency Vancouver Center, Vancouver, British Columbia, Canada. 4. Musculoskeletal Oncology Service, British Columbia Cancer Agency Vancouver Center, Vancouver, British Columbia, Canada. 5. Division of Neuroradiology, Department of Radiology, Vancouver General Hospital, Vancouver, British Columbia, Canada; Department of Radiology, British Columbia's Children's Hospital Vancouver, British Columbia, Canada.
Abstract
PURPOSE: To retrospectively determine the efficacy and safety of cryoablation in patients with desmoid tumors (DTs) over a 10-year period at a single institution. MATERIALS AND METHODS: Between February 25, 2010, and February 25, 2020, 25 patients (age, 12-80 years) with 26 lesions (mean preprocedural tumor volume was 237 cm3) were treated over 44 cryoablation procedures. Eleven patients were treated with first-line therapy. Fourteen patients had previous medical therapy, radiotherapy, and/or surgery. Subsequent clinical follow-up, imaging outcomes, and safety were analyzed for technical success, change in total lesion volume (TLV) and viable tumor volume (VTV), modified response evaluation criteria in solid tumors (mRECIST), progression-free survival (PFS) for tumor progression and symptom recurrence, symptom improvement, and procedure-related complications. Symptomatic improvement was defined as documentation of relief of pain (partial or complete) and/or functional impairment. RESULTS: All procedures were technically successful. At 7-12 months, median changes in TLV and VTV were -6.7% (P = .809) and -43.7% (P = .01), respectively. At 10-12 months, the mRECIST responses were complete response, 0%; partial response, 61.5% (8/13); stable disease, 30.8% (4/13); and progressive disease, 7.7% (1/13). The median PFS for tumor progression and symptom recurrence were not reached, with a median follow-up of 15.3 and 21.0 months, respectively. Symptomatic relief (partial or complete) was achieved in 96.9% (32/33) of patients. One major complication was noted (2.4%). CONCLUSIONS: In this retrospectively identified cohort, cryoablation was effective and safe for the local control of extra-abdominal DTs in short-term follow-up.
PURPOSE: To retrospectively determine the efficacy and safety of cryoablation in patients with desmoid tumors (DTs) over a 10-year period at a single institution. MATERIALS AND METHODS: Between February 25, 2010, and February 25, 2020, 25 patients (age, 12-80 years) with 26 lesions (mean preprocedural tumor volume was 237 cm3) were treated over 44 cryoablation procedures. Eleven patients were treated with first-line therapy. Fourteen patients had previous medical therapy, radiotherapy, and/or surgery. Subsequent clinical follow-up, imaging outcomes, and safety were analyzed for technical success, change in total lesion volume (TLV) and viable tumor volume (VTV), modified response evaluation criteria in solid tumors (mRECIST), progression-free survival (PFS) for tumor progression and symptom recurrence, symptom improvement, and procedure-related complications. Symptomatic improvement was defined as documentation of relief of pain (partial or complete) and/or functional impairment. RESULTS: All procedures were technically successful. At 7-12 months, median changes in TLV and VTV were -6.7% (P = .809) and -43.7% (P = .01), respectively. At 10-12 months, the mRECIST responses were complete response, 0%; partial response, 61.5% (8/13); stable disease, 30.8% (4/13); and progressive disease, 7.7% (1/13). The median PFS for tumor progression and symptom recurrence were not reached, with a median follow-up of 15.3 and 21.0 months, respectively. Symptomatic relief (partial or complete) was achieved in 96.9% (32/33) of patients. One major complication was noted (2.4%). CONCLUSIONS: In this retrospectively identified cohort, cryoablation was effective and safe for the local control of extra-abdominal DTs in short-term follow-up.
Authors: Bimal Mayur Kumar Vora; Peter L Munk; Nagavalli Somasundaram; Hugue A Ouellette; Paul I Mallinson; Adnan Sheikh; Hanis Abdul Kadir; Tien Jin Tan; Yet Yen Yan Journal: PLoS One Date: 2021-12-23 Impact factor: 3.240